Free Trial

Integrated Diagnostics (IDHC) Competitors

Integrated Diagnostics logo
GBX 0.34 0.00 (0.00%)
As of 08:25 AM Eastern

IDHC vs. DXRX, AGL, YGEN, ABDX, PRM, GDR, GENI, VRCI, DMTR, and LLAI

Should you be buying Integrated Diagnostics stock or one of its competitors? The main competitors of Integrated Diagnostics include Diaceutics (DXRX), ANGLE (AGL), Yourgene Health (YGEN), Abingdon Health (ABDX), Proteome Sciences (PRM), genedrive (GDR), GENinCode (GENI), Verici Dx (VRCI), Deepmatter Group (DMTR), and LungLife AI (LLAI). These companies are all part of the "diagnostics & research" industry.

Integrated Diagnostics vs. Its Competitors

Diaceutics (LON:DXRX) and Integrated Diagnostics (LON:IDHC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Integrated Diagnostics has a net margin of 17.21% compared to Diaceutics' net margin of -10.90%. Integrated Diagnostics' return on equity of 30.45% beat Diaceutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Diaceutics-10.90% -7.15% -6.06%
Integrated Diagnostics 17.21%30.45%9.69%

Diaceutics currently has a consensus target price of GBX 160, suggesting a potential upside of 39.96%. Given Diaceutics' stronger consensus rating and higher possible upside, analysts plainly believe Diaceutics is more favorable than Integrated Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Diaceutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Integrated Diagnostics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

52.4% of Diaceutics shares are held by institutional investors. Comparatively, 43.0% of Integrated Diagnostics shares are held by institutional investors. 34.3% of Diaceutics shares are held by company insiders. Comparatively, 34.0% of Integrated Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Integrated Diagnostics has higher revenue and earnings than Diaceutics. Diaceutics is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Diaceutics£26.08M3.70-£2.84M-£3.37-33.91
Integrated Diagnostics£23.29T0.00£4.01T£0.0312.56

In the previous week, Diaceutics' average media sentiment score of 0.00 equaled Integrated Diagnostics'average media sentiment score.

Company Overall Sentiment
Diaceutics Neutral
Integrated Diagnostics Neutral

Diaceutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Integrated Diagnostics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Summary

Integrated Diagnostics beats Diaceutics on 8 of the 14 factors compared between the two stocks.

Get Integrated Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IDHC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IDHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IDHC vs. The Competition

MetricIntegrated DiagnosticsDiagnostics & Research IndustryMedical SectorLON Exchange
Market Cap£9.95B£796.47M£5.53B£2.96B
Dividend Yield14.08%5.44%5.22%5.02%
P/E Ratio12.562.1327.81148.63
Price / Sales0.00492.24429.10277,924.39
Price / CashN/A11.4226.2127.97
Price / Book0.002.738.024.58
Net Income£4.01T£334.07B£3.18B£5.90B
7 Day Performance-0.59%-1.80%2.88%1.43%
1 Month Performance-6.11%-4.47%1.66%4.77%
1 Year Performance18.80%-8.38%34.25%82.68%

Integrated Diagnostics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IDHC
Integrated Diagnostics
N/AGBX 0.34
flat
N/A+20.9%£9.95B£23.29T12.566,692Gap Down
DXRX
Diaceutics
N/AGBX 114.10
+1.0%
GBX 160
+40.2%
-10.0%£96.29M£26.08M-33.84151
AGL
ANGLE
1.8081 of 5 stars
GBX 6.52
-3.5%
GBX 40
+514.0%
-57.6%£21.00M£2.44M-0.96650Gap Up
YGEN
Yourgene Health
N/AN/AN/AN/A£16.43M£29.67M-51.50253
ABDX
Abingdon Health
N/AGBX 6.55
-6.4%
N/A-31.6%£12.69M£3.84M-15.9384
PRM
Proteome Sciences
N/AGBX 3.48
+14.5%
N/A-18.9%£10.27M£10.88B-2.52240Gap Down
GDR
genedrive
N/AGBX 1.49
+6.7%
N/A-17.4%£8.48M£1.50M-0.4243Gap Up
GENI
GENinCode
N/AGBX 2.50
+11.1%
N/A-67.3%£4.44M£2.67M-0.732,300Positive News
Gap Up
VRCI
Verici Dx
N/AGBX 1
-11.1%
N/A-82.7%£3.04M£5.91M-0.5819Gap Down
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04M-0.11N/AGap Down
LLAI
LungLife AI
N/AGBX 3.50
-17.6%
N/A-75.9%£1.16M£33.87K-0.2815Gap Down
High Trading Volume

Related Companies and Tools


This page (LON:IDHC) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners